Fusion Net Income From Continuing Ops from 2010 to 2024
| FUSN Stock | USD 21.55 0.03 0.14% |
Net Loss | First Reported 2010-12-31 | Previous Quarter -91.3 M | Current Value -86.8 M | Quarterly Volatility 37.9 M |
Check Fusion Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Fusion Pharmaceuticals' main balance sheet or income statement drivers, such as Net Interest Income of 3.7 M, Interest Income of 9 M or Depreciation And Amortization of 1.5 M, as well as many indicators such as Price To Sales Ratio of 320, Dividend Yield of 0.0 or PTB Ratio of 2.98. Fusion financial statements analysis is a perfect complement when working with Fusion Pharmaceuticals Valuation or Volatility modules.
Fusion | Net Income From Continuing Ops |
Latest Fusion Pharmaceuticals' Net Income From Continuing Ops Growth Pattern
Below is the plot of the Net Income From Continuing Ops of Fusion Pharmaceuticals over the last few years. It is Fusion Pharmaceuticals' Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Fusion Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
| Net Income From Continuing Ops | 10 Years Trend |
|
Net Income From Continuing Ops |
| Timeline |
Fusion Net Income From Continuing Ops Regression Statistics
| Arithmetic Mean | (33,560,150) | |
| Coefficient Of Variation | (112.99) | |
| Mean Deviation | 34,353,133 | |
| Median | (6,264,000) | |
| Standard Deviation | 37,920,032 | |
| Sample Variance | 1437.9T | |
| Range | 85.1M | |
| R-Value | (0.85) | |
| Mean Square Error | 424.2T | |
| R-Squared | 0.73 | |
| Significance | 0.000055 | |
| Slope | (7,225,153) | |
| Total Sum of Squares | 20131T |
Fusion Net Income From Continuing Ops History
About Fusion Pharmaceuticals Financial Statements
There are typically three primary documents that fall into the category of financial statements. These documents include Fusion Pharmaceuticals income statement, its balance sheet, and the statement of cash flows. Fusion Pharmaceuticals investors use historical funamental indicators, such as Fusion Pharmaceuticals's Net Income From Continuing Ops, to determine how well the company is positioned to perform in the future. Although Fusion Pharmaceuticals investors may use each financial statement separately, they are all related. The changes in Fusion Pharmaceuticals's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Fusion Pharmaceuticals's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Fusion Pharmaceuticals Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Fusion Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Net Loss | -91.3 M | -86.8 M |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectAdditional Information and Resources on Investing in Fusion Stock
When determining whether Fusion Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Fusion Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Fusion Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Fusion Pharmaceuticals Stock:Check out the analysis of Fusion Pharmaceuticals Correlation against competitors. To learn how to invest in Fusion Stock, please use our How to Invest in Fusion Pharmaceuticals guide.You can also try the ETFs module to find actively traded Exchange Traded Funds (ETF) from around the world.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Fusion Pharmaceuticals. If investors know Fusion will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Fusion Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.40) | Revenue Per Share 0.028 | Quarterly Revenue Growth (1.00) | Return On Assets (0.23) | Return On Equity (0.47) |
The market value of Fusion Pharmaceuticals is measured differently than its book value, which is the value of Fusion that is recorded on the company's balance sheet. Investors also form their own opinion of Fusion Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Fusion Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Fusion Pharmaceuticals' market value can be influenced by many factors that don't directly affect Fusion Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Fusion Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Fusion Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Fusion Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.